Post by ALK

"Let’s dare to try new things." Jacob Glenting, EVP of Corporate, Portfolio & Product Strategy, sees an expanded disease area focus as key to ALK’s success. “After more than a century in allergy, our Allergy+ strategy expanded the therapeutic areas we want to lead in. Beyond respiratory allergy, we’re now committed to growing our impact in anaphylaxis, food allergy, and new related areas. This extended focus reinforces our growth ambition and dedication to help many more people with allergy worldwide.” Having been with ALK since 2007, Glenting highlights the value of bringing in new perspectives to our work: “Welcoming new colleagues across our global organisation and collaborating with external partners gives us an important outside-in perspective, to the benefit of the people we’re aiming to help. At the same time, our strong, innovative and welcoming culture enables us to build teams with a great sense of belonging and where people feel safe to openly debate. Together, this helps us adapt and execute faster and better in a complex international environment.” Looking ahead, Glenting sees our continued courage to do things differently as fundamental for our ability to succeed with our ambitious mission at ALK: “Stepping in to new fields, there are always a lot of unknowns. Success is really about belief and daring to create something new. My ambition for ALK is that we will continue to dream, have confidence in our mission, and dare for the benefit of our patients, physicians and employees.”